Page 346 - Glucose Monitoring Devices

References 353

[76] Hovorka R, Elleri D, Thabit H, Allen JM, Leelarathna L, El-Khairi R, et al. Overnight
closed-loop insulin delivery in young people with type 1 diabetes: a free-living,
randomized clinical trial. Diabetes Care 2014;37(5):1204e11.
[77] Nimri R, Muller I, Atlas E, Miller S, Kordonouri O, Bratina N, et al. Night glucose
control with MD-logic artificial pancreas in home setting: a single blind, randomized
crossover trialdinterim analysis. Pediatric Diabetes 2014;15(2):91e9.
[78] Nimri R, Muller I, Atlas E, Miller S, Fogel A, Bratina N, et al. MD-Logic overnight
control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover
trial. Diabetes Care 2014;37(11):3025e32.
[79] Thabit H, Elleri D, Leelarathna L, Allen JM, Lubina-Solomon A, Stadler M, et al.
Unsupervised home use of overnight closed-loop system over 3 to 4 weeks - pooled
analysis of randomized controlled studies in adults and adolescents with type 1
diabetes. Diabetes, Obesity and Metabolism 2014.
[80] Thabit H, Tauschmann M, Allen JM, Leelarathna L, Hartnell S, Wilinska ME, et al.
Home use of an artificial beta cell in type 1 diabetes. New England Journal of Medicine
2015;373(22):2129e40.
[81] Anderson SM, Raghinaru D, Pinsker JE, Boscari F, Renard E, Buckingham BA, et al.
Multinational home use of closed-loop control is safe and effective. Diabetes Care
2016;39(7):1143e50.
[82] Kropff J, Del Favero S, Place J, Toffanin C, Visentin R, Monaro M, et al. 2 month
evening and night closed-loop glucose control in patients with type 1 diabetes under
free-living conditions: a randomised crossover trial. The Lancet Diabetes and Endocri-
nology 2015;3(12):939e47.
[83] Thabit H, Lubina-Solomon A, Stadler M, Leelarathna L, Walkinshaw E, Pernet A,
et al. Home use of closed-loop insulin delivery for overnight glucose control in adults
with type 1 diabetes: a 4-week, multicentre, randomised crossover study. The Lancet
Diabetes and Endocrinology 2014;2(9):701e9.
[84] de Bock MI, Roy A, Cooper MN, Dart JA, Berthold CL, Retterath AJ, et al. Feasibility
of outpatient 24-hour closed-loop insulin delivery. Diabetes Care 2015;38(11):
e186e7.
[85] Forlenza GP, Deshpande S, Ly TT, Howsmon DP, Cameron F, Baysal N, et al.
Application of zone model predictive control artificial pancreas during extended use
of infusion set and sensor: a randomized crossover-controlled home-use trial. Diabetes
Care 2017;40(8):1096e102.
[86] Tauschmann M, Allen JM, Wilinska ME, Thabit H, Acerini CL, Dunger DB, et al.
Home use of day-and-night hybrid closed-loop insulin delivery in suboptimally
controlled adolescents with type 1 diabetes: a 3-week, free-living, randomized cross-
over trial. Diabetes Care 2016;39(11):2019e25.
[87] El-Khatib FH, Balliro C, Hillard MA, Magyar KL, Ekhlaspour L, Sinha M, et al. Home
use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1
diabetes: a multicentre randomised crossover trial. The Lancet 2017;389(10067):
369e80.
[88] Leelarathna L, Dellweg S, Mader JK, Allen JM, Benesch C, Doll W, et al. Day and
night home closed-loop insulin delivery in adults with type 1 diabetes: three-center
randomized crossover study. Diabetes Care 2014;37(7):1931e7.
[89] Tauschmann M, Thabit H, Bally L, Allen JM, Hartnell S, Wilinska ME, et al. Closed-
loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre,
12-week randomised trial. Lancet 2018;392(10155):1321e9.